EVAX - CIK 0001828253
The table below shows Evaxion Biotech A/S's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q1 2022 | Q3 2021 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $2.17M | $2.75M | $2.94M | $4.11M | $4.80M | $4.42M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $2.21M |
| $1.98M |
| $2.74M |
| $2.15M |
| $1.59M |
| $1.50M |
| Operating income | - | - | - | - | - | - |
| Income tax | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - |
| EPS (diluted) | - | - | - | - | - | - |